Location History:
- Paris, FR (2008 - 2013)
- Sceaux, FR (2012 - 2022)
Company Filing History:
4 out of 96 
1 out of 5,094 
1 out of 1 Years Active: 2008-2022
Title: Fabrice Andre: Innovator in Cancer Prognosis and Treatment
Introduction
Fabrice Andre is a prominent inventor based in Sceaux, France. He has made significant contributions to the fields of genetics and medicine, particularly in cancer research. With a total of 4 patents, his work focuses on improving patient outcomes in cancer treatment.
Latest Patents
One of his latest patents involves the use of specific gene expressions for the prognosis of patients with triple negative breast cancer (TNBC). This invention relates to the expression values of genes such as GBP 1, HLF, CXCL13, and SULT1E1, which can estimate the prognosis of distant relapse-free survival or overall survival for patients who have undergone neoadjuvant chemotherapy. Another notable patent addresses the treatment of cancer using TLR3 agonists. This invention outlines improved methods for treating cancers by assessing the expression of TLR3 receptors in cancer cells.
Career Highlights
Fabrice Andre has worked with esteemed institutions such as the Institut Gustave Roussy and the Centre National de la Recherche Scientifique. His research has been pivotal in advancing the understanding of cancer treatment and prognosis.
Collaborations
He has collaborated with notable colleagues, including Laurence Zitvogel and Jean-Christophe Sabourin, contributing to a rich exchange of ideas and innovations in the field.
Conclusion
Fabrice Andre's work exemplifies the intersection of innovation and medicine, particularly in the fight against cancer. His patents and collaborations continue to pave the way for advancements in cancer prognosis and treatment.